Magnetic Resonance Imaging (MRI)



MR sagittal image of human head

- Non-invasive and safe technique
- Great spatial resolution (μm scale)
- Outstanding diagnostic capability

A MR-image represents a map of the intensity of the ^{1}H-NMR signal of water protons

The contrast is mainly generated by difference in the relaxation times (T_1 and T_2) of water protons

Nuclear spin relaxation processes

T_1 Relaxation (Spin-Lattice Relaxation)



T_2 Relaxation (Spin-Spin Relaxation)



T_1 ca. 5 T_2

Contrast Agents (CA)

The purpose of a CA is to reduce T_1 (parallel to B_0) or T_2 (perpendicular to B_0) in order to obtain an hyper- or ipo-intense signal, respectively, in short times and with a better signal to noise ratio.

T_1 contrast agents (positive = hyper-intense signal): paramagnetic metal complexes Fe(III), Mn(II), Gd(III)

T_2 contrast agents (negative = ipo-intense signal): Small super-Paramagnetic Iron Oxide nanoparticles (SPIO) and Ultra-Small super-Paramagnetic Iron Oxide NPs (USPIO)

MRI CA's must have a catalytic (i.e. amplified) effect

agenti extracellulari non-specifici, organo-specifici e del sangue



Defect of the blood-brain barrier after stroke shown in MRI. T1-weighted images: left image = without; right image = with contrast medium administration

Il tempo di rilassamento del momento di spin elettronico del Gd(III) è molto più lungo che per gli altri ioni lantanidici (stato di spin totalmente simmetrico)

Ln	La^{3+}	Ce^{3+}	Pr^{3+}	Nd^{3+}	Sm^{3+}	Eu^{3+}	Gd^{3+}	Tb^{3+}	Dy^{3+}	Ho^{3+}	Er^{3+}	Tm^{3+}	Yb^{3+}	Lu^{3+}
$\mu_{eff}/\mu B$ cald.	0.00	2.54	3.58	3.68	0.85	0.00	7.94	9.72	10.63	10.60	9.59	7.57	4.53	0.00
$\chi/10^{-32}m^3$	0.0	5.6	11.2	11.4	0.6	6.0	55.1	82.7	99.2	98.5	80.3	50.0	18.0	0
$\Delta\chi_{ax}/10^{-32}m^3$	0	2.1	3.4	1.7	0.2	-2.3	0	42.1	34.7	18.5	-11.6	-21.9	-8.3	0
$\Delta\chi_{rh}/10^{-32}m^3$	0	0.7	2.1	0.4	-0.1	-1.6	0	11.2	20.3	5.8	-8.6	-20.1	-5.8	0



PCS = *Pseudo-Contact Shift*

PRE = *Paramagnetic Relaxation Enhancement*

il raggio della sfera gialla indica la distanza dal nucleo di metallo alla quale i protoni subiscono un significativo accorciamento del tempo di rilassamento dello spin nucleare

~40% MRI scans use a Gd CA

~40 million MRI scans/year use a Gd CA worldwide

i.e. ~50 tons of Gd

9 commercially used Gd CA

Market > 1 billion $/year

The technique has a low sensitivity: gram quantities of Gd compounds are used in each scan. This causes toxicity problems (nephrogenic systemic fibrosis)

The Gd(III) ion is quite toxic (LD_{50} = 0.2 mmol·kg^{-1})

Some commercial T_1 contrast agents

(extracellular fluid CAs)



Gd-DOTA
Dotarem®
(Guerbet)



Gd-HP-DO3A
ProHance®
(Bracco)

Typical dose =
0.1 – 0.3 mmoles/kg



Gd-BT-DO3A
Gadovist®
(Schering)



Gd-DTPA
Magnevist®
(Schering)



Gd-DTPA-BMA
Omniscan®
(Amersham)



Gd-DTPA-BMEA
OptiMARK®
(Mallinckrodt)

Tipicamente una patologia viene individuata per via di **variazioni anatomiche** (e.g. arterie più strette) oppure **fisiologiche** (e.g. barriera ematoencefalica permeabile, danneggiata).

Relassività (*relaxivity*)

La **relassività r_1** ($mM^{-1}\ s^{-1}$) di un CA è la capacità di una sua soluzione 1 mM di **aumentare** la velocità di rilassamento longitudinale R_1 (= $1/T_1$) del momento di spin nucleare dei protoni dell'acqua

Parameters that affect Relaxivity

Teoria di Solomon-Bloembergen-Morgan (*SBM Theory*)



Typical values of relaxivity for Gd(III) complexes: 5 s^{-1} mM^{-1}

[Gd] > 125 μM per dare un contrasto visibile

Teoria di Solomon-Bloembergen-Morgan (*SBM Theory*)



DOTA family


DOTA


DOTAM


DOTP


$DOTP^{R}$


DO3A


DO3MA


$DO3P^{R}$


DO3AP


$DO3AP^{R}$


DO3ACE


$DO3AMBn^{O\text{-}N}$


$DO3Apy^{NO}$


$DO3Apy^{NO\text{-}C}$


NBnDOTMA


TRITA


$(DO3AP^{ABn})_2CS$


DO3APhenOH

DTPA family



DTPA



DTTAP



DTTAP^{R}



EPTPA



DTTA-*N*-CE



DTTA-*N'*-CE



DTPA-bis(amide)



BOPTA



bipy(DTTA)$_2$

Nuovi leganti polidentati per CA di Gd(III)



pyDO3A



pyDO2AP



pyDO3P



AAZTA



2,3-HOPO



H(2,2)-1,2-HOPO



[Gd{tren(1-Me-3,2-hopo)$_3$}(H_2O)$_2$]

Strategie per aumentare τ_M





Blood pool contrast agents



Vasovist®



Binding of the C.A. to serum albumin increases its tumbling time (τ_R)



5 min after
0.1 mmol/kg i.v.
of extracellular CA



5 min after
0.015 mmol/kg i.v.
of angiographic ca

Targeted CA’s per MRI

Un CA commerciale di Gd, con una relassività di circa 5 $mM^{-1} \cdot s^{-1}$, per dare un contrasto visibile deve raggiungere una **concentrazione di almeno 125 mM**.

Towards molecular imaging with MRI

The very low concentration of the target requires the delivery of a high number, and possibly efficient, Gd(III) centres

C > 125 μM

Several strategies can be adopted

- Gd-chelates covalently or non-covalently linked to biocompatible polymer (proteins, polysaccharides, etc…)
- Self-assembling of complexes (e.g. micelles)
- Use of Gd-loaded nanoparticles (e.g. liposomes,…)



CEST Contrast Agents

Chemical Exchange Saturation Transfer

composti mobili con protoni in scambio lento con l'acqua di *bulk*



$$k_{CEST} < \Delta\omega$$

CEST and PARACEST agents: saturation offset



isotropo

Ln	La^{3+}	Ce^{3+}	Pr^{3+}	Nd^{3+}	Sm^{3+}	Eu^{3+}	Gd^{3+}	Tb^{3+}	Dy^{3+}	Ho^{3+}	Er^{3+}	Tm^{3+}	Yb^{3+}	Lu^{3+}
$\mu_{eff}/\mu B$ cald.	0.00	2.54	3.58	3.68	0.85	0.00	7.94	9.72	10.63	10.60	9.59	7.57	4.53	0.00
$\chi/10^{-32}m^3$	0.0	5.6	11.2	11.4	0.6	6.0	55.1	82.7	99.2	98.5	80.3	50.0	18.0	0
$\Delta\chi_{ax}/10^{-32}m^3$	0	2.1	3.4	1.7	0.2	-2.3	0	42.1	34.7	18.5	-11.6	-21.9	-8.3	0
$\Delta\chi_{rh}/10^{-32}m^3$	0	0.7	2.1	0.4	-0.1	-1.6	0	11.2	20.3	5.8	-8.6	-20.1	-5.8	0



PRE = *Paramagnetic Relaxation Enhancement*

PCS = *Pseudo-Contact Shift*

determina la variazione di chemical shift indotta da ciascuno ione sui nuclei vicini e le iso-superfici rappresentano la grandezza e il segno del chemical shift


z
Ln^{3+}-OH_2
y
Amide protons
x



B = $[Tb\text{-}DOTAMGly]^{-}$
C = $[Eu\text{-}DOTAMGly]^{-}$
D = $[Tb\text{-}DOTAMGly]^{-}$ + $[Eu\text{-}DOTAMGly]^{-}$

Responsive (*smart*) CA

Sensore della β-galattossidasi





L’aggiunta del solo CA 0,5 mM (sinistra) aumenta di poco il contrasto, ma l’aggiunta dell’enzima β-galattossidasi 4 mM (destra) genera un notevole aumento di contrasto.

T_2 contrast agents
super-paramagnetic iron oxide particles (SPIO)
Ø = 60 – 250 nm

Pre-Clinical Agent	Commercial Name	MR Target	Status
AMI-25	Ferumoxide, Feridex, Endoderm	Liver	Approved
OMP	Abdoscan	Bowel	Approved
AMI-121	Gastromark, Ferumoxsil, Lumirem	Bowel	Approved
SHU555A	Resovist	Liver	Approved (EU, Japan, Australia), Phase III (USA)
AMI-227	Combidex, Sinerem, Ferumoxtran	Lymph Node Metastases	Phase III
CODE 7228	Feraheme, Ferumoxytol	Vasculature	Phase II

Coating biocompatibile: destrano, amido, glicosammino-glicano, silossani organici, copolimeri stirene-divinilbenzene solfonati,….